Handelsbanken Fonder AB Buys 69,440 Shares of Gilead Sciences, Inc. $GILD

Handelsbanken Fonder AB boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,164,320 shares of the biopharmaceutical company's stock after purchasing an additional 69,440 shares during the quarter. Handelsbanken Fonder AB owned about 0.09% of Gilead Sciences worth $129,088,000 as of its most recent SEC filing.

• 3 Cash-Rich Stocks With High Growth Potential Right Now

Several other institutional investors have also recently made changes to their positions in GILD. One Wealth Advisors LLC increased its stake in Gilead Sciences by 34.8% during the 2nd quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company's stock valued at $1,016,000 after purchasing an additional 2,364 shares in the last quarter. Ariel Investments LLC increased its position in shares of Gilead Sciences by 7.7% during the first quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company's stock worth $48,229,000 after acquiring an additional 30,630 shares in the last quarter. Simplify Asset Management Inc. raised its holdings in shares of Gilead Sciences by 148.6% in the 2nd quarter. Simplify Asset Management Inc. now owns 52,890 shares of the biopharmaceutical company's stock worth $5,864,000 after acquiring an additional 31,618 shares during the last quarter. Sivik Global Healthcare LLC lifted its position in Gilead Sciences by 25.0% in the 2nd quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company's stock valued at $5,544,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Wealth Management Associates Inc. acquired a new position in Gilead Sciences during the 2nd quarter valued at about $255,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Analysts Set New Price Targets

GILD has been the topic of a number of recent research reports. Daiwa Capital Markets raised their target price on Gilead Sciences from $128.00 to $129.00 and gave the company an "outperform" rating in a report on Thursday, November 13th. Citigroup raised their price objective on Gilead Sciences from $125.00 to $135.00 and gave the company a "buy" rating in a research note on Wednesday, October 8th. Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $140.00 to $145.00 and gave the stock an "overweight" rating in a report on Friday, October 31st. Scotiabank assumed coverage on shares of Gilead Sciences in a report on Thursday, November 13th. They issued a "sector outperform" rating and a $140.00 target price for the company. Finally, Royal Bank Of Canada raised their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the company a "sector perform" rating in a research report on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $130.45.

• Biotech Sector May Flip to Market Leader by Year-End

Check Out Our Latest Research Report on GILD

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $124.99 on Friday. The company has a market capitalization of $155.07 billion, a P/E ratio of 24.90, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. The company's 50-day moving average is $118.23 and its 200 day moving average is $113.37. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a fifty-two week low of $88.07 and a fifty-two week high of $128.70.

• 3 Biotech Giants Gaining From U.S. Sales and Policy Shifts

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm's quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the company posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be paid a $0.79 dividend. The ex-dividend date is Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.5%. Gilead Sciences's dividend payout ratio is presently 48.99%.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $125.23, for a total transaction of $313,075.00. Following the completion of the transaction, the chief financial officer owned 154,555 shares in the company, valued at approximately $19,354,922.65. This represents a 1.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction dated Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total value of $1,193,900.00. Following the completion of the sale, the chief executive officer directly owned 581,203 shares of the company's stock, valued at approximately $69,389,826.17. This trade represents a 1.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 125,146 shares of company stock valued at $15,148,441 in the last three months. 0.27% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Featured Articles

• Five stocks we like better than Gilead Sciences
• Retail Stocks Investing, Explained
• Datavault AI Just Raised Guidance by 400%—Are You Paying Attention?
• Investing in the High PE Growth Stocks
• Peter Thiel Dumps NVIDIA and Slashes Tesla Stake—Is the AI Bubble About to Pop?
• NYSE Stocks Give Investors a Variety of Quality Options
• Why Lithium Americas Could Be a 2030 Power Play—Not a 2025 One

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Gilead Sciences Right Now?

Before you consider Gilead Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.

While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here